How Language Develops, What Goes Wrong, And Why It Matters: Following The Early Language In Victoria Study To Age 13
Funder
National Health and Medical Research Council
Funding Amount
$857,242.00
Summary
One in five children start school with low language. Little is known about the long term effects on developmental, educational attainment and other outcomes later in life. In this landmark study we will track the children's language, literacy and wellbeing from ages 8 to 12 years. We will capture the children's ability as they finish their primary school education and prior to the crucial transfer to high school.
Neural Mechanisms Of Language Facilitation In Aphasia Due To Transcranial Direct Current Stimulation.
Funder
National Health and Medical Research Council
Funding Amount
$523,192.00
Summary
This project will assess the underlying neural mechanisms by which neurostimulation improves impaired language functions after stroke (aphasia). This will be accomplished by using a novel combination of functional magnetic resonance imaging and simultaneous transcranial direct current stimulation (tDCS) administered to different brain regions. These studies will provide crucial information necessary to optimise future clinical trials that combine tDCS with language therapy.
The Contribution Of Home Language Exposure To Intergenerational Transmission Of Inequality
Funder
National Health and Medical Research Council
Funding Amount
$1,281,706.00
Summary
The amount of language stimulation from parent to child could be the key driver behind intergenerational inequality. Children learn language through social interaction and this study will significantly enhance our current understanding of exposure to language in the child's home environment. The study will demonstrate how inequalities in the early years have far reaching consequences for later health and development.
IMPROVE - Investigating Medication Re-Purposing To Reduce Risk Of OVarian Cancer And Extend Survival
Funder
National Health and Medical Research Council
Funding Amount
$430,196.00
Summary
Ovarian cancer is the 6th most common cause of cancer death in women and the proportion of women who die from their disease has not improved substantially over time. This large-scale study will use de-identified data from the Pharmaceutical Benefits Scheme, the Australian Cancer Database and the National Death Index to investigate whether medications commonly used for other conditions can help decrease the risk of ovarian cancer developing or improve survival from ovarian cancer after diagnosis.